Another SBM potential 10 bagger springs to life – Phytopharm taking out 52 wk high

1 mins. to read

We covered Phytopharm extensively in the June edition of our magazine (see here page 13 – and updated in the latest edition in which we set out the investment case for a potentially very attractive return on the stock should the company’s Phase 2 trials of their primary drug Cogane, which is being used to treat Parkinsons disease, go well.

The share chart below shows some pretty decent stock accumulation in recent weeks and the shares are now probing the 52 week highs – 2 signs that seasoned traders use to alert them to an extension of the trend. Perhaps news is beginning to leak as to how the trials are progressing? If the drug is working and they get through Phase II then expect 30p+ in the months ahead.


Take a look at our record on the About Us page. We have seeded 3 dedicated “follow me” funds that are managed in accordance with our measured leverage and risk controlled basis that we advocate in this magazine – 

1. A diversifed yet concentrated Oil Explorers fund

2. A diversified yet concentrated Natural Resources fund and

3. A Special Situations/Global Macro fund.

If you would like details on this unique “follow me” system and how you can gain exposure to these funds ahead of an official launch, email us at editor@spreadbetmagazine quoting “FOLLOW ME”.

Comments (1)

Leave a Reply

Your email address will not be published. Required fields are marked *